Vasiliki Pelekanou
0000-0002-8431-1927
Publication & Citation Trends
Most Cited Works
Publications
122 total
Abstract ND09: BAY 3547926: Novel targeted radionuclide therapy for hepatocellular carcinoma
Cited by 1
Semantic Scholar
CCR8 positive Tregs and their correlation with immunotherapy response in advanced non-small cell lung cancer (NSCLC).
Cited by 0
Semantic Scholar
BANTAM-01: A Multicenter, Open-Label, First-in-Human Phase 1 Dose Escalation and Expansion Study of 225Ac-GPC3 (BAY 3547926) in Patients with Advanced Hepatocellular Carcinoma
Cited by 0
Semantic Scholar
1200 Artificial intelligence image models optimizing tumor vs immune cell profiling for accurate biomarker analysis in NSCLC precision drug development OA
Cited by 0
Semantic Scholar
1276 Leveraging artificial intelligence (AI) models delineating tumor vs immune cell expression for scalable biomarker analysis of clinical trial samples: a digital image analysis approach for NSCLC OA
Cited by 0
Semantic Scholar
Development of machine learning–powered models for prostate cancer HRD prediction.
Cited by 1
Semantic Scholar
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial OA
Cited by 9
Semantic Scholar
Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer
Cited by 1
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(42)
Estrogen and related hormone effects
(23)
HER2/EGFR in Cancer Research
(20)
Immunotherapy and Immune Responses
(19)
Advanced Breast Cancer Therapies
(19)
Frequent Co-Authors
Affiliations
Jiwaji University
Université Libre de Bruxelles
University of British Columbia
University of Crete
Bayer (United States)